COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Physician Summary:

Age 3 - 21 (inclusive); Newly Dx: RT+ Vincristine +/- Carboplatin f/b Maint +/- Continuous Isotretinoin

COG-ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma

Physician Summary:

< Age 22; Newly Diagnosed. Treatment: Vorinostat + RT  vs Temozolomide + RT vs Bevacizumab + RT f/b Bevacizumab Maintenance 

ANBL0032: Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Physician Summary:

< age 30; High Risk: Anti-GD2 Following ASCR

AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

Physician Summary:

< age 30, Newly Dx Higher Risk: VCR, AMD, DOXO per DD4A for 2 cycles + DD4A vs Regimen M

COG-AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

Physician Summary:

< age 30; All drugs commercially provided.  For Schema, contact pediatric nurses at GRCOP 616.391.1230.

AREN0321: Treatment of High Risk Renal Tumors

Physician Summary:

≤ age 30, Newly Diagnosed Stage I-IV, Chemo –vs- Surgery Only (Ancillary AREN03B2 Required)

AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)

Physician Summary:

Age 0-30; Newly Diag. T-Cell ALL; Methotrexate, Nelarabine and Augmented BFM Therapy (Prerequisite AALL03B1)

AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

Physician Summary:

  ≤ age 30; Initial Intermed-Risk Relapse of B-precursor: Standard VCR Dosing vs Intensive VCR Dosing

AALL07P1:  A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Physician Summary:

< Age 31; Relapsed B-precursor ALL, relapsed T-cell ALL and relapsed T-LL: Bortezomib w/Intensive Re-Induction Therapy

COG-ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazol to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Physician Summary:

AML Patients < Age 30; Caspofungin vs Fluconazol to Prevent Fungal Infections

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib  and Sorafenib for Patients with High Allelic Ratio FLT3/ITD. 

Physician Summary:

< Age 30; Contact GRCOP pediatric nurses at 391-1230 for additional information on this study.

COG-AAML07P1: A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia

Physician Summary:

≤ age 21; Recurrent, Refractory or Secondary AML: Bortezomib Combined w/ Reinduction Chemotherapy

COG- AHOD0831 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma

Physician Summary:

< Age 21; Stage III/IV w/ B Symptoms; Newly Diagnosed: See Fast Facts for Tx Schema. Call Pediatric Nurses at 616.391.1230 with questions.

AALL07P1:  A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Physician Summary:

< Age 31; Relapsed B-precursor ALL, relapsed T-cell ALL and relapsed T-LL: Bortezomib w/Intensive Re-Induction Therapy

COG-AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.

Physician Summary:

Age: 0-50; Non-Metastatic.  Contact GRCOP Pediatric Oncology nurses at 616.486.6156 for additional information.

ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

Physician Summary:

Newly Dx, < 50 years old: VAC +/- XRT

ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).

Physician Summary:

< age 50; Newly Diagnosed: VAC vs VAC alternating w/ VI; Includes XRT

AOST0331: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy

Physician Summary:

≤ age 40; High Grade Osteosarcoma: Resectable/Histological Response to Pre-Operative Chemotherapy

AOST06P1: Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma

Physician Summary:

≤ age 40; No Prior Chemo; Feasibility & Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemo